Table 1.
Demographics and clinical characteristics of women with metastatic breast cancer depending on physical activity level.
| Total physical activity (MET-hours/week) | Total N = 833 | |||
|---|---|---|---|---|
| Light physical activity (< 10 MET-hour/week) N = 97 (12%) |
Moderate physical activity ([10;50[ MET-hour/week) N = 575 (69%) |
Vigorous physical activity (≥ 50 MET-hour/week) N = 161 (19%) |
||
| Demographic | ||||
| Age at primitive tumor diagnosis | ||||
| N | 97 | 573 | 161 | |
| Mean ± sd | 62.4 (± 12.0) | 52.1 (± 12.8) | 50.8 (± 11.1) | 53.1 (± 12.8) |
| Age at metastatic diagnosis | ||||
| N | 97 | 575 | 161 | |
| Mean ± sd | 67.2 (± 11.6) | 56.9 (± 13.1) | 55.7 (± 11.4) | 57.8 (± 13.1) |
| Weight, kg | ||||
| N | 97 | 572 | 161 | 830 |
| Mean ± sd | 69.5 (± 16.6) | 68.3 (± 14.7) | 64.6 (± 12.9) | 67.7 (± 14.7) |
| Missing data | 0 | 3 | 0 | 3 |
| Body mass index, kg/m | ||||
| Underweight (< 18.5 kg/m2) | 6 (6.2%) | 18 (3.2%) | 7 (4.3%) | 31 (3.7%) |
| Normal weight (< 25 kg/m2) | 36 (37.1%) | 274 (48.0%) | 91 (56.5%) | 401 (48.4%) |
| Overweight (25–30 kg/m2) | 27 (27.8%) | 163 (28.5%) | 44 (27.3%) | 234 (28.2%) |
| Obese (> 30 kg/m2) | 28 (28.9%) | 116 (20.3%) | 19 (11.8%) | 163 (19.7%) |
| Missing data | 0 | 4 | 0 | 4 |
| PS ECOG | ||||
| 0–1 | 55 (70.5%) | 413 (90.8%) | 128 (93.4%) | 596 (89.0%) |
| 2–3 | 23 (29.5%) | 42 (9.2%) | 9 (6.6%) | 74 (11.0%) |
| Missing data | 19 | 120 | 24 | 163 |
| Metastatic at diagnosis | ||||
| No | 54 (55.7%) | 363 (63.5%) | 104 (64.6%) | 521 (62.8%) |
| Yes | 31 (32.0%) | 136 (23.8%) | 37 (23.0%) | 204 (24.6%) |
| Undetermined | 12 (12.4%) | 73 (12.8%) | 20 (12.4%) | 105 (12.7%) |
| Missing data | 0 | 3 | 0 | 3 |
| Education | ||||
| High School | 64 (73.6%) | 274 (51.1%) | 65 (43.3%) | 403 (52.1%) |
| 1- to 2-year university degree | 17 (19.5%) | 156 (29.1%) | 48 (32.0%) | 221 (28.6%) |
| > 2-year university degree | 6 (6.9%) | 106 (19.8%) | 37 (24.7%) | 149 (19.3%) |
| Missing data | 10 | 39 | 11 | 60 |
| Smokers | ||||
| Yes | 26 (27.4%) | 255 (44.8%) | 67 (41.6%) | 348 (42.2%) |
| No | 69 (72.6%) | 314 (55.2%) | 94 (58.4%) | 477 (57.8%) |
| Missing data | 2 | 6 | 0 | 8 |
| Clinical | ||||
| Molecular subtype | ||||
| HER2 positive | 12 (12.6%) | 96 (16.7%) | 36 (22.4%) | 144 (17.3%) |
| Luminal | 71 (74.7%) | 394 (68.5%) | 103 (64.0%) | 568 (68.4%) |
| Triple negative | 12 (12.6%) | 85 (14.8%) | 22 (13.7%) | 119 (14.3%) |
| Missing data | 2 | 0 | 0 | 2 |
| Number of death | 63 | 337 | 75 | 475 |
| HER2 positive | 8 | 47 | 8 | 63 |
| Luminal | 42 | 223 | 46 | 311 |
| Triple negative | 12 | 67 | 21 | 100 |
| Median between diagnosis and metastatic disease (months)[range] | 73.5 [0.7;335.5] | 49.0 [0.1;462.5] | 57.2 [0.3;322.5] | 53.5 [0.1;462.5] |
| < 24 months | 14 (14.4%) | 133 (71.9%) | 38 (20.5%) | 185 (100%) |
| ≥ 24 months | 52 (53.6%) | 306 (68.9%) | 86 (19.4%) | 444 (100%) |
| CA 15.3 [U/ml] | ||||
| N | 76 | 449 | 118 | 643 |
| Mean ± sd | 338.9 (± 694.6) | 212.1 (± 543.0) | 198.8 (± 499.4) | 224.7 (± 556.2) |
| Missing data | 21 | 126 | 43 | 190 |
| Lymphocytes [G/l] | ||||
| N | 73 | 446 | 122 | 641 |
| Mean ± sd | 1.9 (± 1.9) | 1.8 (± 1.1) | 1.8 (± 1.2) | 1.9 (± 1.2) |
| Missing data | 24 | 129 | 39 | 192 |
| Number of metastatic sites | ||||
| < 3 sites | 60 (61.9%) | 381 (66.3%) | 120 (74.5%) | 561 (67.3%) |
| ≥ 3 sites | 37 (38.1%) | 194 (33.7%) | 41 (25.5%) | 272 (32.7%) |
| Metastatic localization | ||||
| Brain | 8 (8.2%) | 31 (5.4%) | 6 (3.7%) | 45 (5.4%) |
| Bones | 70 (72.2%) | 400 (69.6%) | 105 (65.2%) | 575 (69.0%) |
| Pulmonary | 33 (34.0%) | 152 (26.4%) | 39 (24.2%) | 224 (26.9%) |
| Node | 31 (32.0%) | 189 (32.9%) | 57 (35.4%) | 277 (33.3%) |
| Pleura | 19 (19.6%) | 59 (10.3%) | 17 (10.6%) | 95 (11.4%) |
| Skin | 12 (12.4%) | 35 (6.1%) | 8 (5.0%) | 55 (6.6%) |
| Hepatic | 33 (34.0%) | 202 (35.1%) | 51 (31.7%) | 286 (34.3%) |
| Loco regional | 12 (12.4%) | 109 (19.0%) | 36 (22.4%) | 157 (18.8%) |
| Others | 10 (10.3%) | 76 (13.2%) | 19 (11.8%) | 105 (12.6%) |
| Adjuvant chemotherapy | ||||
| Yes | 38 (39.2%) | 314 (54.6%) | 86 (53.4%) | 438 (52.6%) |
| No | 59 (60.8%) | 261 (45.4%) | 75 (46.6%) | 395 (47.4%) |
| Dual inhibition of HER2 | ||||
| Yes | 3 (27.3%) | 32 (35.6%) | 13 (39.4%) | 86 (64.2%) |
| No | 8 (72.7%) | 58 (64.4%) | 20 (60.6%) | 48 (35.8%) |
| Missing data | 1 | 6 | 3 | 10 |